The relationship between changes in functional cardiac parameters following anthracycline therapy and carbonyl reductase 3 and glutathione s transferase pi polymorphisms

Journal of Chemotherapy

Volumn 24, Issue 5, 2012, Pages 285-291

  Volkan Salanci, Bilge ^a   Aksoy, Hakan ^a   Kiratli, Özgen Pinar ^a   Tülümen, Erol ^a   Giler, Nilüfer ^b   Öksüzoglu, Berna ^c   Tokgözoǧlu, Late ^a   Erbaş, Belkis ^a   Alikaşifoǧlu, Mehmet ^a  

^a Department of Nuclear Medicine ^*  (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Anthracycline cardiotoxicity; Cardiac monitoring; CBR3 p.V244M polymorphism; Functional cardiac parameters; GSTP1 p.1105V polymorphism

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; BLEOMYCIN; CARBONYL REDUCTASE; CARBONYL REDUCTASE 3; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIRUBICIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE P1; GONADORELIN DERIVATIVE; PREDNISOLONE; TAMOXIFEN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ALLELE; ARTICLE; BLOOD POOL SCINTISCANNING; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DNA SEQUENCE; ECHOCARDIOGRAPHY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VOLUME; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; ALCOHOL OXIDOREDUCTASES; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; FEMALE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; HEART FUNCTION TESTS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84866641237     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000037     Document Type: Article

References (26)

1. de Graaf H, Dolsma WV, Willemse PH, van der Graaf WT, Sleijfer DT, de Vries EG, et al. Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer. Br J Cancer. 1997;76:943-5.
2. Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:3159-65.
3. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13:699-709.
4. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics. 1992;89:942-9.
5. Von Hoff DD, Layard MW, Basa P, Davis HL, Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-7.
6. Mordente A, Meucci E, Martorana GE, Giardina B, Minotti G. Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life. 2001;52:83-8.
7. Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equili-brium radionuclide angiocardiography in the current era. J Nucl Cardiol. 2003;10:132-9.
8. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47-58.
9. Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep. 2009;61:154-71.
10. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer. 2008;112:2789-95.
11. Deng S, Wojnowski L. Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol. 2007;7:129-34.
12. Forrest GL, Gonzalez B, Tseng W, Li X, Mann J. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in trans-genic mice. Cancer Res. 2000;60:5158-64.
13. Lakhman SS, Ghosh D, Blanco JG. Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3). Drug Metab Dispos. 2005;33:254 7.
14. Ali-Osman F, Akande O, Antoun G, Mao JX, J. Buolamwini, Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem. 1997;272:10004-12.
15. Kuehne R, Reuter E. High RBC labeling efficiency by controlling pretinning with the modified in vivo/in vitro labeling method. J Nucl Med Technol. 1999;27:222-6.
16. Schwartz RG, McKenzie WB, Alexander J, Sager P, D'Souza A, Manatunga A, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardio-graphy. Am J Med. 1987;82:1109-18.
17. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-63.
18. Moser EC, Noordijk EM, van Leeuwen FE, le Cessie S, Baars JW, Thomas J, et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood. 2006;107:2912-9.
19. Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubi-cin cardiotoxicity in lymphoma patients. Br J Cancer. 2002;86:1697-700.
20. Marchandise B, Schroeder E, Bosly A, Doyen C, Weynants P, Kremer R, et al. Early detection of doxorubicin cardio-toxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J. 1989;118:92-8.
21. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardio-toxicity after anthracycline therapy in children: a systematic review. Ann Oncol. 2002;13:819-29.
22. Fan L, Goh BC, Wong CI, Sukri N, Lim SE, Tan SH, et al. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet Genomics. 2008;18:621-31.
23. Lal S, Sandanaraj E, Wong ZW, Ang PC, Wong NS, Lee EJ, et al. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 2008;99:2045-54.
24. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphi-sms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis. 1998;19:275-80.
25. Sun N, Sun X, Chen B, Cheng H, Feng J, Cheng L, et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2010;65:437-46.
26. Aplenc R, Blanco J, Leisering W, Davies S, Relling M, Robison L, et al. Polymorphisms in candidate genes in patients with congestive heart failure (CHF) after childhood cancer: a report from the Childhood Cancer Survivor Study (CCSS). J Clin Oncol. 2006;24:9004.